Emergent BioSolutions (EBS) Cash from Financing Activities (2010 - 2026)

Emergent BioSolutions' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$11.4 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 2750.0% year-over-year to -$11.4 million in Q1 2026; TTM through Mar 2026 was -$147.6 million, a 36.13% increase from a year earlier, with the FY2025 full-year figure at -$136.6 million, up 28.11% from the prior year.
• Cash from Financing Activities improved to -$11.4 million in Q1 2026 per EBS's latest filing, from -$113.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $353.1 million in Q4 2022 and bottomed at -$486.9 million in Q2 2023.
• The 5-year median for Cash from Financing Activities is -$11.4 million (2026), against an average of -$23.1 million.
• Across the five-year window, Cash from Financing Activities jumped 4686.0% in 2022 and plunged 22880.0% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $353.1 million in 2022, then sank by 98.67% to $4.7 million in 2023, then sank by 89.36% to $500000.0 in 2024, then plunged by 22880.0% to -$113.9 million in 2025, then jumped by 89.99% to -$11.4 million in 2026.
• Per Business Quant, the three latest EBS Cash from Financing Activities figures stand at -$11.4 million (Q1 2026), -$113.9 million (Q4 2025), and -$15.9 million (Q3 2025).